NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. focuses on developing innovative therapies targeting cardiometabolic diseases, with a special emphasis on obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology firm formed in 2017 and headquartered in Boston, US.

It specializes in therapies for cardiometabolic conditions. The company underwent a reverse merger with Gemphire Therapeutics Inc. in December 2019, becoming a publicly listed entity. Recent funding included a Private Placement/Follow on round in October 2021, raising USD 14.

000 mn, which contributed to a total amount raised of USD 14. 000 mn. The company has engaged in 5 deals, with the most recent deal occurring on January 19, 2021. The current CEOs are Gil Price and Hyung Kim.

NeuroBo Pharmaceuticals, Inc. offers two primary product candidates: DA-1726, a dual oxyntomodulin (OXM) analog agonist designed to stimulate both glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), and DA-1241, a G-Protein-Coupled Receptor 119 (GPR119) agonist aimed at treating MASH. These products are in clinical trials, targeting patients with obesity and MASH in North America and Europe for potential distribution upon regulatory approval. In 2023, NeuroBo Pharmaceuticals, Inc.

reported an EBITDA of USD -15. 88 mn. Revenue is generated through partnerships with healthcare providers, research institutions, and pharmaceutical companies, primarily through collaboration agreements and licensing arrangements for its proprietary products, DA-1726 and DA-1241, in exchange for milestone payments and royalties. Pricing for these products will be determined following regulatory approval, ensuring competitive alignment within the biotechnology market.

NeuroBo Pharmaceuticals, Inc. plans to expand its portfolio by advancing DA-1726 and DA-1241 through clinical trials, with a focus on securing regulatory approval. The company aims to target both North American and European markets for product distribution. The recent funding will support ongoing clinical trials and potential market entry strategies.

Following the successful fundraising in October 2021, the company is well-positioned to capitalize on new partnerships and enhance its market reach as it continues to develop therapies for cardiometabolic diseases.